Montreal, Canada, March 23, 2016 --(PR.com
)-- Arylide Life Sciences announces that it has signed an exclusive, long term agreement with Stratpharma AG to distribute its novel line of medical products in Canada. As of March 1st, 2016, these innovative and proven products are available to Canadian healthcare professionals and patients:
Stratamed® is the first and only advanced film-forming full contact flexible wound dressing that can be used on non-epithelialized wounds and compromised skin. Stratamed is bacteriostatic and inert. Stratamed represents a breakthrough treatment for rapid re-epithelialization and abnormal scar prevention. For use in general and cosmetic surgery, laser device treatments, dermabrasion and chemical peels.
StrataXRT® is an easy-to-apply innovative full contact flexible wound dressing for the prevention and treatment of radiation dermatitis. Acute radiation-induced skin reactions are an inevitable consequence of radiation therapy and occur in up to 95% of patients receiving treatment depending on treatment location.
StrataXRT helps to preserve the skin's integrity, by reducing the side effects of ionizing radiation. In dry desquamation, StrataXRT protects the fragile epidermis and maintains the skin’s integrity, preventing the outmost layers from excessive sloughing. In moist desquamation, StrataXRT protects the dermal stroma from long-term deterioration whilst optimizing the environment for the reparative process and reducing the risk of infection.
Stratamark® is the first registered medical product specifically designed for the prevention and treatment of all types of stretch marks with clinical proven efficacy. Stretch marks affect up to 90% of pregnant women with an average incidence of 65%-75% during pregnancy. Stratamark dramatically reduces the incidence of stretch marks to 18%. For the treatment of stretch marks, Stratamark significantly reduces the severity, colour, visibility and itching associated with stretch marks. Stratamark can be used in combination with other stretch marks treatments including laser therapy. Stratamark is suitable for pregnant women, breastfeeding mothers, children and people with sensitive skin.
Strataderm® is a new generation rapidly drying, non-sticky, transparent, silicone gel formulation for the effective treatment of both old and new scars as well as abnormal scar prevention, in the form of hypertrophic scars and keloids. Strataderm can be applied once daily.
“Healthcare professionals, patients and consumers alike now have new options to effectively treat and manage a wide range of dermal issues,” says Arylide President and CEO, Michael Fiorentino.
Visit our website at www.arylide.com.
Arylide Life Sciences is a privately held Canadian company that commercializes healthcare products aimed at improving people’s lives. Arylide seeks to build strategic partnerships with companies interested in turnkey solutions to gain market presence and achieve portfolio expansion.
Stratpharma AG is a developer of novel topical medical devices and pharmaceutical products headquartered in Basel, Switzerland. The company specializes in the commercialization of topical medical devices and pharmaceutical products focusing in the areas of cosmetic and aesthetic dermatology, plastic surgery, burns, wounds and scar management. Stratpharma is ISO 13485 certified for the design, development and manufacture of medical devices. Stratpharma products are registered in more than 80 countries and sold in over 50 countries all over the world.